The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
|Slideshows|March 2, 2017
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Author(s)Samantha J. Peterson
Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Advertisement
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
Advertisement
Related to this article
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Here's some of what is coming soon to NeurologyLive® this week.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
3
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
4
Congress Passes ACT for ALS Reauthorization, Extending Research Programs
5